Beyond cardiovascular risk: Implications of Familial hypercholesterolemia on cognition and brain function
2024 (English)In: Ageing Research Reviews, ISSN 1568-1637, E-ISSN 1872-9649, Vol. 93, article id 102149Article in journal (Refereed) Published
Abstract [en]
Familial hypercholesterolemia (FH) is a metabolic condition caused mainly by a mutation in the low-density lipoprotein (LDL) receptor gene (LDLR), which is highly prevalent in the population. Besides being an important causative factor of cardiovascular diseases, FH has been considered an early risk factor for Alzheimer's disease. Cognitive and emotional behavioral impairments in LDL receptor knockout (LDLr-/-) mice are associated with neuroinflammation, blood-brain barrier dysfunction, impaired neurogenesis, brain oxidative stress, and mitochondrial dysfunction. Notably, today, LDLr-/- mice, a widely used animal model for studying cardiovascular diseases and atherosclerosis, are also considered an interesting tool for studying dementia. Here, we reviewed the main findings in LDLr-/- mice regarding the relationship between FH and brain dysfunctions and dementia development.
Place, publisher, year, edition, pages
ELSEVIER IRELAND LTD , 2024. Vol. 93, article id 102149
Keywords [en]
Cholesterol; Memory; Blood-brain barrier Neuroinflammation LDL; receptorLDLr-/-mice
National Category
Geriatrics
Identifiers
URN: urn:nbn:se:liu:diva-201021DOI: 10.1016/j.arr.2023.102149ISI: 001156174200001PubMedID: 38056504Scopus ID: 2-s2.0-85180602649OAI: oai:DiVA.org:liu-201021DiVA, id: diva2:1840197
Note
Funding Agencies|Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF) [00193-00000229/2021-21, 00193- 00001324/2019-27]; Fundacao de Apoio a Pesquisa do Rio grande do Sul (FAPRGS); Fundacao de Apoio a Pesquisa de Santa Catarina (FAPESC); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [424809-2018-4]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/STINT ) [888 81.465507/2019-01]; Instituto Nacional de Ciencia e Tecnologia e Neuro-ImunoModulacao (INCT-NIM) [485489/2014-1]
2024-02-222024-02-222025-03-18Bibliographically approved